Gary Nachman
Stock Analyst at Raymond James
(2.83)
# 1,547
Out of 4,829 analysts
101
Total ratings
56.52%
Success rate
0.02%
Average return
Main Sectors:
Stocks Rated by Gary Nachman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Reiterates: Outperform | $218 → $220 | $190.07 | +15.75% | 14 | Feb 3, 2025 | |
| SDGR Schrödinger | Maintains: Outperform | $25 → $28 | $24.17 | +15.85% | 5 | Nov 13, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $275 → $298 | $270.19 | +10.29% | 7 | Nov 1, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $37 | $29.37 | +25.98% | 1 | Sep 27, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Strong Buy | $20 | $2.48 | +706.45% | 1 | Sep 27, 2024 | |
| PCRX Pacira BioSciences | Maintains: Outperform | $41 → $37 | $25.09 | +47.47% | 13 | Jul 31, 2024 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $19 | $11.89 | +59.80% | 1 | Jul 10, 2024 | |
| AMGN Amgen | Reinstates: Market Perform | n/a | $274.76 | - | 1 | Mar 28, 2024 | |
| SRRK Scholar Rock Holding | Initiates: Strong Buy | $30 | $32.46 | -7.58% | 5 | Mar 28, 2024 | |
| AQST Aquestive Therapeutics | Initiates: Outperform | $7 | $2.85 | +145.61% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $3 | $0.52 | +475.82% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $103.58 | - | 11 | Sep 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $4 | $7.60 | -47.37% | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $3.15 | +852.38% | 4 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $67 | $33.53 | +99.82% | 2 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $32 | $2.06 | +1,453.40% | 1 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $16 → $14 | $8.96 | +56.25% | 2 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $75 | $9.42 | +696.18% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $43 → $40 | $6.75 | +492.59% | 8 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $11 → $10 | $17.96 | -44.32% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $18.61 | +61.20% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $810 → $750 | $2.85 | +26,215.79% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $8 | $4.78 | +67.36% | 2 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $21 | $24.34 | -13.72% | 5 | May 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $14 | $2.48 | +464.52% | 2 | Jun 14, 2018 |
AbbVie
Feb 3, 2025
Reiterates: Outperform
Price Target: $218 → $220
Current: $190.07
Upside: +15.75%
Schrödinger
Nov 13, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $24.17
Upside: +15.85%
Alnylam Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $275 → $298
Current: $270.19
Upside: +10.29%
LENZ Therapeutics
Sep 27, 2024
Initiates: Outperform
Price Target: $37
Current: $29.37
Upside: +25.98%
Achieve Life Sciences
Sep 27, 2024
Initiates: Strong Buy
Price Target: $20
Current: $2.48
Upside: +706.45%
Pacira BioSciences
Jul 31, 2024
Maintains: Outperform
Price Target: $41 → $37
Current: $25.09
Upside: +47.47%
Bausch + Lomb
Jul 10, 2024
Initiates: Outperform
Price Target: $19
Current: $11.89
Upside: +59.80%
Amgen
Mar 28, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $274.76
Upside: -
Scholar Rock Holding
Mar 28, 2024
Initiates: Strong Buy
Price Target: $30
Current: $32.46
Upside: -7.58%
Aquestive Therapeutics
Mar 28, 2024
Initiates: Outperform
Price Target: $7
Current: $2.85
Upside: +145.61%
Mar 28, 2024
Initiates: Outperform
Price Target: $3
Current: $0.52
Upside: +475.82%
Sep 29, 2023
Initiates: Market Perform
Price Target: n/a
Current: $103.58
Upside: -
Mar 3, 2023
Maintains: Market Perform
Price Target: $5 → $4
Current: $7.60
Upside: -47.37%
Mar 1, 2023
Maintains: Outperform
Price Target: $35 → $30
Current: $3.15
Upside: +852.38%
Feb 23, 2023
Maintains: Outperform
Price Target: $70 → $67
Current: $33.53
Upside: +99.82%
Feb 22, 2023
Maintains: Outperform
Price Target: $40 → $32
Current: $2.06
Upside: +1,453.40%
Feb 17, 2023
Downgrades: Market Perform
Price Target: $16 → $14
Current: $8.96
Upside: +56.25%
Nov 14, 2022
Maintains: Outperform
Price Target: $90 → $75
Current: $9.42
Upside: +696.18%
Nov 9, 2022
Maintains: Market Perform
Price Target: $43 → $40
Current: $6.75
Upside: +492.59%
Nov 7, 2022
Maintains: Market Perform
Price Target: $11 → $10
Current: $17.96
Upside: -44.32%
Nov 4, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $18.61
Upside: +61.20%
Aug 11, 2022
Maintains: Outperform
Price Target: $810 → $750
Current: $2.85
Upside: +26,215.79%
Aug 10, 2022
Maintains: Market Perform
Price Target: $15 → $8
Current: $4.78
Upside: +67.36%
May 11, 2020
Maintains: Market Perform
Price Target: $20 → $21
Current: $24.34
Upside: -13.72%
Jun 14, 2018
Maintains: Outperform
Price Target: $24 → $14
Current: $2.48
Upside: +464.52%